Lymphoma Clinical Trials in Xiamen, Fujian
20 recruitingXiamen, Fujian, China
Showing 1–20 of 20 trials
Recruiting
Phase 3
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines630 enrolled155 locationsNCT06943872
Recruiting
Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Marginal Zone LymphomaRelapsed/Refractory Follicular Lymphoma
BeiGene780 enrolled277 locationsNCT05100862
Recruiting
Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Diffuse Large B Cell Lymphoma
Merck Sharp & Dohme LLC1,046 enrolled246 locationsNCT06717347
Recruiting
Phase 1
GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL
Non-Hodgkin LymphomaRefractory LymphomaChimeric Antigen Receptor T-cell
The First Affiliated Hospital of Xiamen University45 enrolled1 locationNCT06875063
Recruiting
Phase 2
A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)
Primary Central Nervous System LymphomaPCNSL
Tongji Hospital110 enrolled3 locationsNCT07350850
Recruiting
Phase 3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
Follicular Lymphoma ( FL)
Genmab1,095 enrolled265 locationsNCT06191744
Recruiting
Phase 3
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Diffuse Large B Cell Lymphoma
Genmab360 enrolled177 locationsNCT06508658
Recruiting
Phase 3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Refractory Follicular LymphomaFollicular LymphomaRelapsed/Refractory Follicular Lymphoma
Epizyme, Inc.612 enrolled229 locationsNCT04224493
Recruiting
Phase 3
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Peripheral T Cell Lymphoma
Dizal Pharmaceuticals218 enrolled50 locationsNCT07234162
Recruiting
Phase 1
A Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
Non-Hodgkin Lymphoma
Hangzhou GluBio Pharmaceutical Co., Ltd.110 enrolled13 locationsNCT06219356
Recruiting
Phase 2
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
Diffuse Large B Cell LymphomaRelapsed and Refractory
The First Affiliated Hospital of Xiamen University22 enrolled1 locationNCT06651853
Recruiting
Phase 2
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
Diffuse Large Cell B-lymphoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.55 enrolled24 locationsNCT06854445
Recruiting
Phase 2
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
Follicular LymphomaRelapsed Non Hodgkin LymphomaRefractory B-Cell Lymphoma
The First Affiliated Hospital of Xiamen University33 enrolled1 locationNCT06158386
Recruiting
Phase 2
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
Peripheral T Cell LymphomaRelapsed Peripheral T-Cell LymphomaRefractory T-Cell Lymphoma
The First Affiliated Hospital of Xiamen University33 enrolled1 locationNCT06151106
Recruiting
Phase 2
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
DLBCL - Diffuse Large B Cell LymphomaFollicular Lymphoma
The First Affiliated Hospital of Xiamen University38 enrolled1 locationNCT06151080
Recruiting
Phase 2
AZA Combined With RCHOP in P53-mutated DLBCL.
DLBCL - Diffuse Large B Cell LymphomaTP53
The First Affiliated Hospital of Xiamen University52 enrolled1 locationNCT06158399
Recruiting
Phase 2
Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma
LymphomaFollicular LymphomaRefractory Lymphoma
The First Affiliated Hospital of Xiamen University30 enrolled1 locationNCT06826118
Recruiting
Phase 2
Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma
Follicular LymphomaNewly Diagnosed
The First Affiliated Hospital of Xiamen University39 enrolled1 locationNCT06553352
Recruiting
Not Applicable
Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy
Marginal Zone Lymphoma
The First Affiliated Hospital of Xiamen University36 enrolled1 locationNCT06478472
Recruiting
Phase 3
A Randomized, Open-label, Multi-center, Phase III Study of Orelabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) vs. R-CHOP Alone in Patients With Treatment-naїve Mantle Cell Lymphoma
Treatment-naїve Mantle Cell Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.356 enrolled22 locationsNCT05051891